Oracle stock price today: ORCL ticks up after hours as April 6 lawsuit deadline nears

Oracle stock price today: ORCL ticks up after hours as April 6 lawsuit deadline nears

February 20, 2026

New York, Feb 19, 2026, 19:01 (EST) — After-hours

Oracle edged up 0.3% to $156.54 in Thursday’s after-hours action. Shares changed hands between $155.24 and $160.00 during the session, with volume coming in around 14.9 million.

That slight uptick doesn’t capture the bigger storyline dogging Oracle these past weeks: investors keep coming back to one question—how quickly all that heavy AI infrastructure spend turns into actual cash for the company.

This matters right now: the company’s pushing to ramp up cloud capacity fast, but doesn’t want to rattle credit markets in the process. Investors are quick to react—if it looks like spending is getting ahead of near-term revenue, the stock usually takes a hit.

Stocks eased back, with the SPY ETF—tracking the S&P 500—off 0.3%. QQQ, which mirrors the Nasdaq 100, dropped 0.4%. Software names weren’t immune: IGV finished the day lower by 0.2%.

Oracle shares picked up 1.43% Wednesday, finishing at $156.17 and beating out Microsoft and Alphabet’s moves, according to MarketWatch data.

Behind the scenes, Oracle and top executives—among them CEO Safra Catz and chairman Larry Ellison—face a shareholder lawsuit, filed Feb. 3 in U.S. District Court in Delaware. Investors accuse the company of overstating how quickly its AI infrastructure CapEx would drive growth.

Investors have until April 6, 2026 to petition the court for the role of “lead plaintiff,” according to law firm notices out this week. The lead plaintiff steers the suit for the proposed class of shareholders. ACCESS Newswire

Oracle faces ongoing scrutiny over how it plans to fund its expansion. Earlier this month, the company laid out a projection: it’s looking to raise $45 billion to $50 billion in 2026, drawing on both debt and share issuance. That breakdown could include as much as $20 billion from at-the-market stock sales, with shares trickling out at current prices. Guggenheim’s analysts read the move as sending a “clear message” to bondholders. Reuters

Still, there are clear risks. Delays in projects or a slowdown in AI capacity demand could leave Oracle wrestling with softer free cash flow for longer—and leaning harder on fresh borrowing. Litigation only piles on more uncertainty and expense.

Looking ahead to Friday and next week, traders are eyeing potential moves tied to the funding plan, along with any new court filings. April 6 is still the key date to watch—the deadline for lead-plaintiff bids.

Stock Market Today

  • Telix Pharmaceuticals Advances Connected Oncology Platform with Positive Phase 1 Glioblastoma Trial and Prostate Cancer Collaborations
    May 28, 2026, 5:56 PM EDT. Telix Pharmaceuticals (ASX:TLX) announced full patient enrolment in its Phase 1 IPAX-2 trial for TLX101-Tx targeting glioblastoma, with no dose-limiting toxicities observed at highest doses. The firm also signed letters of intent to explore prostate cancer collaborations involving PSMA PET imaging, supporting its strategy to develop a connected oncology platform combining brain cancer therapy and prostate cancer imaging-based treatments. While encouraging for TLX101-Tx safety, the update does not alter focus on late-stage trials like IPAX BrIGHT or ProstACT GLOBAL. Telix faces risks including heavy reinvestment and an ongoing SEC subpoena linked to its prostate therapeutics segment. Analysts project Telix's revenue and earnings could reach A$1.2 billion and A$111 million by 2029, implying 22.7% annual growth and significant earnings expansion. Current stock price reflects potential for nearly 93% upside, though uncertainties remain.